EMA lists paediatric priorities for off-patent drugs as new EC funding nears
This article was originally published in Scrip
Following a two-year drought, the European Commission's seventh framework programme (FP7) is to make fresh funding available next year for companies wishing to develop paediatric forms of off-patent drugs.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.